7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline dihydrochloride

Catalog No.: 
ACACZY847
CAS No.: 
866823-63-4
Molecular Formula: 
C13H15Cl2N3
Molecular Weight: 
284.19
7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$112.00InquiryInquiry
25mg98%$155.00InquiryInquiry
50mg98%$248.00InquiryInquiry
100mg98%$402.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline dihydrochloride
IUPAC Name7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline dihydrochloride
MDL No.MFCD12546330
Molecular FormulaC13H15Cl2N3
Molecular Weight284.19
SMILES[H]Cl.[H]Cl.C1(C2)CNCC2C3=CC4=NC=CN=C4C=C13
InChI KeyNZVVYNGXLGJKCW-UHFFFAOYSA-N
Synonym866823-63-4 | Varenicline dihydrochloride | Varenicline (dihydrochloride) | Varenicline | Varenicline-d4 Dihydrochloride (Major) | CHEMBL556954 | 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline dihydrochloride | 7,8,9,10-tetrahydro-6,10-Methano-6H-pyrazino
CAS No.866823-63-4
PubChem CID45263226

Synthetic Route by SureRoute

1. ACACZY847 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWRDZ562 route compound structure diagram
    ACWRDZ562230615-70-0In Stock
  2. Then
  3. ACACZY847 route product structure diagram
    ACACZY847866823-63-4
Inquiry

2. ACACZY847 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACACZY847 route product structure diagram
    ACACZY847866823-63-4
Inquiry

3. ACACZY847 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACACZY847 route product structure diagram
    ACACZY847866823-63-4
Inquiry

Comments (0)